Shares of Arbutus Biopharma Corp (NASDAQ:ABUS) have earned an average rating of “Hold” from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $13.80.

A number of analysts have recently commented on the stock. BidaskClub upgraded shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday. ValuEngine upgraded shares of Arbutus Biopharma from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Chardan Capital reiterated a “buy” rating on shares of Arbutus Biopharma in a research note on Tuesday, January 16th. Zacks Investment Research lowered shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a research note on Thursday, January 18th. Finally, B. Riley assumed coverage on shares of Arbutus Biopharma in a research note on Friday, January 5th. They issued a “buy” rating and a $10.00 price target for the company.

How to Become a New Pot Stock Millionaire

Shares of Arbutus Biopharma (ABUS) traded down $0.35 during mid-day trading on Friday, hitting $5.65. 44,358 shares of the stock were exchanged, compared to its average volume of 161,961. Arbutus Biopharma has a 52-week low of $2.70 and a 52-week high of $8.25. The company has a market capitalization of $333.07, a price-to-earnings ratio of -1.21 and a beta of 1.02. The company has a debt-to-equity ratio of 0.08, a current ratio of 11.03 and a quick ratio of 11.03.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Point72 Asset Management L.P. purchased a new position in shares of Arbutus Biopharma in the third quarter worth approximately $1,393,000. RTW Investments LP boosted its holdings in shares of Arbutus Biopharma by 1.1% in the third quarter. RTW Investments LP now owns 5,266,280 shares of the biopharmaceutical company’s stock worth $32,651,000 after buying an additional 56,457 shares during the last quarter. OxFORD Asset Management LLP boosted its holdings in shares of Arbutus Biopharma by 49.2% in the third quarter. OxFORD Asset Management LLP now owns 124,273 shares of the biopharmaceutical company’s stock worth $778,000 after buying an additional 40,963 shares during the last quarter. Hudson Bay Capital Management LP boosted its holdings in shares of Arbutus Biopharma by 239.0% in the fourth quarter. Hudson Bay Capital Management LP now owns 400,000 shares of the biopharmaceutical company’s stock worth $2,020,000 after buying an additional 282,000 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its holdings in shares of Arbutus Biopharma by 16.6% in the fourth quarter. Victory Capital Management Inc. now owns 150,720 shares of the biopharmaceutical company’s stock worth $761,000 after buying an additional 21,460 shares during the last quarter. 62.14% of the stock is currently owned by institutional investors.

WARNING: “Arbutus Biopharma Corp (ABUS) Receives $13.80 Consensus PT from Brokerages” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2018/03/14/arbutus-biopharma-corp-abus-receives-13-80-consensus-pt-from-brokerages.html.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Analyst Recommendations for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.